PT  - JOURNAL ARTICLE
AU  - Thompson, Ryan C.
AU  - Simons, Nicole W.
AU  - Wilkins, Lillian
AU  - Cheng, Esther
AU  - Del Valle, Diane Marie
AU  - Hoffman, Gabriel E.
AU  - Fennessy, Brian
AU  - Mouskas, Konstantinos
AU  - Francoeur, Nancy J.
AU  - Johnson, Jessica S.
AU  - Lepow, Lauren
AU  - Berichel, Jessica Le
AU  - Chang, Christie
AU  - Beckmann, Aviva G.
AU  - Wang, Ying-chih
AU  - Nie, Kai
AU  - Zaki, Nicholas
AU  - Tuballes, Kevin
AU  - Barcessat, Vanessa
AU  - Cedillo, Mario A.
AU  - Huckins, Laura
AU  - Roussos, Panagiotis
AU  - Marron, Thomas U.
AU  - ,
AU  - Glicksberg, Benjamin S.
AU  - Nadkarni, Girish
AU  - Gonzalez-Kozlova, Edgar
AU  - Kim-Schulze, Seunghee
AU  - Sebra, Robert
AU  - Merad, Miriam
AU  - Gnjatic, Sacha
AU  - Schadt, Eric E.
AU  - Charney, Alexander W.
AU  - Beckmann, Noam D.
TI  - Acute COVID-19 gene-expression profiles show multiple etiologies of long-term sequelae
AID  - 10.1101/2021.10.04.21264434
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.04.21264434
4099  - http://medrxiv.org/content/early/2021/10/05/2021.10.04.21264434.short
4100  - http://medrxiv.org/content/early/2021/10/05/2021.10.04.21264434.full
AB  - Two years into the SARS-CoV-2 pandemic, the post-acute sequelae of infection are compounding the global health crisis. Often debilitating, these sequelae are clinically heterogeneous and of unknown molecular etiology. Here, a transcriptome-wide investigation of this new condition was performed in a large cohort of acutely infected patients followed clinically into the post-acute period. Gene expression signatures of post-acute sequelae were already present in whole blood during the acute phase of infection, with both innate and adaptive immune cells involved. Plasma cells stood out as driving at least two distinct clusters of sequelae, one largely dependent on circulating antibodies against the SARS-CoV-2 spike protein and the other antibody-independent. Altogether, multiple etiologies of post-acute sequelae were found concomitant with SARS-CoV-2 infection, directly linking the emergence of these sequelae with the host response to the virus.Competing Interest StatementS.G. reports consultancy and/or advisory roles for Merck and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Immune Design, Celgene, Janssen R&D, Takeda, and Regeneron.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Protection Program at the Icahn School of Medicine at Mount Sinai (STUDY-20-00341)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll consented data used will be deposited in public repositories upon publication.